



- (51) **International Patent Classification:**
A61K 31/07 (2006.01) *A61P 27/02* (2006.01)
- (21) **International Application Number:**
PCT/US2024/062409
- (22) **International Filing Date:**
31 December 2024 (31.12.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/617,012 02 January 2024 (02.01.2024) US
- (71) **Applicant:** **ALKEUS PHARMACEUTICALS, INC.**
[US/US]; 44 Brattle St, Fl 2, Cambridge, Massachusetts
02138 (US).
- (72) **Inventor:** **SAAD, Leonide C.**; 44 Brattle St, Fl 2, Cam-
bridge, Massachusetts 02138 (US).
- (74) **Agent:** **GODDARD, Christine A.** et al.; Fish & Richard-
son, P.O. Box 1022, Minneapolis, Minnesota 55440-1022
(US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** 10MG TO 35MG OF GILDEURETINOL FOR USE IN THE TREATMENT OF STARGARDT DISEASE




Fig. 3

Age-matched visual acuity of three asymptomatic patients taking gildeuretinol acetate 14 mg capsules daily (bold curves) alongside their untreated Stargardt disease siblings

(57) **Abstract:** Disclosed is a method of treating a patient with Stargardt Disease. Also disclosed is a method of delaying the progression of vision loss in a patient with Stargardt Disease. The methods comprise administering to the patient from 10 mg to 35 mg per day of gildeuretinol acetate.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*